186 related articles for article (PubMed ID: 38216949)
21. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
23. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
24. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.
Trivedi P; Jhala G; De George DJ; Chiu C; Selck C; Ge T; Catterall T; Elkerbout L; Boon L; Joller N; Kay TW; Thomas HE; Krishnamurthy B
Front Immunol; 2024; 15():1370907. PubMed ID: 38533515
[TBL] [Abstract][Full Text] [Related]
25. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.
Zhang Z; Richmond A; Yan C
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806358
[TBL] [Abstract][Full Text] [Related]
27. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
28. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
[TBL] [Abstract][Full Text] [Related]
29. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
30. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
31. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract][Full Text] [Related]
32. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
33. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
Wang L; Yang X; Zhou F; Sun X; Li S
Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
[TBL] [Abstract][Full Text] [Related]
34. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
35. Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway.
Sharma P; Khan MA; Najmi AK; Chaturvedi S; Akhtar M
Med Oncol; 2022 Oct; 39(12):248. PubMed ID: 36209343
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
37. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
38. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation.
Li Y; Wang Z; Yang J; Sun Y; He Y; Wang Y; Chen X; Liang Y; Zhang N; Wang X; Zhao W; Hu G; Yang Q
Mol Cancer; 2024 May; 23(1):102. PubMed ID: 38755678
[TBL] [Abstract][Full Text] [Related]
39. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
[TBL] [Abstract][Full Text] [Related]
40. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
